Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 329

License Grant

The Licensor hereby grants to the Licensee a license under the Licensor IP to research, develop, use, import, make, have made, sell, and offer for sale Licensee Products in the Field in the Territory. Such license shall be exclusive (even as to Licensor) with respect to any development, selling, offering for sale or other Commercialization of Licensee Products in the Field in the Territory, and shall be otherwise non-exclusive.  
Licensor grants a non-exclusive, royalty-free license to use and display the Licensor Trademarks, solely in connection with the Commercialization of Licensee Products in the promotional materials, packaging, and labeling.

License Property

The Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.

A Bacteriophage is a virus that parasitizes a bacterium by infecting it and reproducing inside it. They are seen as a possible therapy against multi-drug-resistant strains of many bacteria.

Field of Use

Field means genetically modified bacteriophages using synthetic biology, and the production of bacteriophages using synthetic biology, for bacteriophage-containing human therapeutics for use in the treatment of bacterial infections associated with acute and chronic wounds, and the treatment of acute and chronic Pseudomonas aeruginosa lung infections, and the treatment of infections of Clostridium difficile.

Licensee now desires to become exclusive channel collaborator with respect to such technology for the purpose of developing the Bacteriophage Program.

License Grant

The Licensor hereby grants to the Licensee a License under the Licensor IP to research, develop, use, make, have made, sell, import, and offer for sale Licensee Products in the Field in the worldwide territory.

The Licensor hereby grants to the Licensee a non-exclusive, royalty-free License to use and display the Trademarks, solely in connection with the Commercialization of Licensee Products in the promotional materials, packaging, and labeling.

License Property

Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression

Licensor Channel Technology means Licensor's current and future technology directed towards the design, identification, culturing, and/or production of genetically modified cells.

Such License shall be exclusive, even as to the Licensor, with respect to any development, selling, making or having made using (except for uses in connection with research), importing, offering for sale or other Commercialization of Licensee Products in the Field, and shall be otherwise non-exclusive.

Field of Use

Field means the development, breeding, hatching, and farming of genetically modified finfish to be used for human food consumption.

The Licensee is a company involved in bringing together biological sciences and molecular technology to enable an aquaculture industry capable of large-scale, efficient, and environmentally sustainable production of high quality seafood.

License Grant

The Irish Licensor hereby grants to the Company a worldwide, non-exclusive, non-transferable license, without any right to sublicense, under the Irish Licensor's Patent Rights and Know-How to
(a) make or have made Licensed Antibody Phage Display Materials;
(b) solely for Research and Development purposes, conduct Antibody Phage Display;
(c) make or have made Research Quantities of a Licensed Immunoglobulin;
(d) transfer Antibody Phage Display Materials;
(e) transfer Research Quantities of a Licensed Immunoglobulin or Licensed Immunoglobulin Information to a Company Collaborator or a Development Partner of the Company;
(f) sell, offer to sell, import and export Licensed Immunoglobulins;
(g) use Licensed Immunoglobulins; and
(h) use, offer for sale, sell, import and export Products for use in the treatment, prophylaxis, diagnosis or monitoring of a human disease state or condition.

The Company is willing to grant the Irish Licensor non-exclusive licenses, in order to permit the Irish Licensor to engage in certain research, development and commercial activities.

License Property

The Company's patented phage display technology rapidly selects antibodies, peptides and small proteins that bind with high affinity and specificity to therapeutic targets.

Licensed antibody phage display materials means any collection or library of polynucleotide sequences which encodes at least one Immunoglobulin and which is contained in filamentous bacteriophage and/or bacteriophage or phagemid cloning vectors capable of propagation in bacteria; or any collection or library of bacteriophage wherein an Immunoglobulin is expressed as a fusion protein comprising an Immunoglobulin or at least a functionally operating region of an antibody variable region and an outer surface polypeptide of a bacteriophage.

License Grant

Licensor grants a license under the Licensor IP to research, develop, use, make, have made, sell, and offer for sale Licensee, an affiliate, Products in the Field in the Territory.

Licensor grants a non-exclusive license to use and display the Licensor Trademarks, solely in connection with the Commercialization of Licensor Products in the promotional materials, packaging, and labeling for Licensee Products.

Licensor grants a non-exclusive license under the Licensor IP to use, make, have made, sell, and offer for sale Licensee Products for Permitted Ancillary Commercial Uses in the Territory.

License Property

Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.

Licensor Channel Technology means Licensors current and future technology directed towards the design, identification, culturing, and/or production of genetically modified cells.

Licensee Product means any product in the Field that is created, produced, developed, or identified in whole or in part, directly or indirectly, by or on behalf of Licensee during the Term through use or practice of Licensor Channel Technology, Licensor IP, or the Licensor Materials.

Channel-Related Program IP is all Inventions made with, using, or otherwise incorporating Licensor Channel Technology, together with all Patent rights and other intellectual property rights therein.

Alkaloid Program means the channel collaboration between the Parties as established and governed by this Agreement.

Licensor Trademarks means those trademarks related to the Licensor Channel Technology.

Field of Use

Field means the fermentative production of Alkaloids through genetically modified cell-lines and substrate feeds for use as Active Pharmaceutical Ingredients or as commercially-sold intermediates in the manufacture of Active Pharmaceutical Ingredients. The Field specifically excludes the use of Alkaloids for the manufacture of diacylhydrazines or any other molecule that controls an ecdysone-based switch.

License Grant

The Licensor and the Belgium Licensor grant the Licensee an exclusive license under the IP to research, develop, use, import, export, make, have made, sell, and offer for sale Licensor Products in the Field in the Territory.

The Licensors grant the Licensee a non-exclusive, royalty-free license to use and display the Licensors Trademarks solely in connection with the Commercialization of Licensor Products.

License Property

The Licensor owns or controls proprietary technology relating to the identification, design and production of genetically modified cells, DNA vectors and in vivo control of expression.

The Licensor Subsidiary controls proprietary technology known as AG013 and a related L. lactis expression platform for the treatment of diseases and conditions of the oral cavity, throat, and esophagus.

Field of Use

The Licensors grant an exclusive license in the Field under the AG013 Regulatory Rights, including an exclusive right in the Field to make reference to for purposes of conducting clinical trials and obtaining regulatory approval for AG013 as a Licensee Product.

License Grant

The Licensee entered into an Exclusive Channel Collaboration Agreement with the Licensor that governs a channel collaboration arrangement governing a strategic collaboration for the development and commercialization of genetically modified and non-genetically modified autologous fibroblasts and autologous dermal cells in the United States.

License Property

Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.

Field of Use

Genetically-modified fibroblasts are used to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions.

A fibroblast is a type of biological cell that synthesizes the extracellular matrix and collagen, produces the structural framework (stroma) for animal tissues, and plays a critical role in wound healing. Fibroblasts are the most common cells of connective tissue in animals.

The Field includes the enhanced production and purification of non-genetically modified autologous fibroblasts for all aesthetic and therapeutic indications; the enhanced production and purification of non-genetically modified autologous dermal cells for aesthetic and therapeutic treatment of dermal, vocal cord, and periodontal indications; the development of genetically modified autologous fibroblasts for all aesthetic and therapeutic indications; and the development of genetically modified autologous dermal cells for aesthetic and therapeutic treatment of dermal, vocal cord, and periodontal indications.

License Grant

The general purpose of the exclusive channel collaboration described in this Agreement will be to use the Licensor Channel Technology to research, develop and Commercialize products for use in the Field.

Licensor grants a world-wide license under the Licensor IP to research, develop, use, make, have made, import, export, market, sell, and offer for sale Licensee Products in the Field in the Territory.

Licensor grants a non-exclusive license to use and display the Licensor Trademarks, solely in connection with the Commercialization of Licensee Products in the promotional materials, packaging, and labeling for Licensee Products.

This agreement also includes a non-exclusive grant back to Licensor.

License Property

Licensor has expertise in and owns or controls proprietary technology relating to the identification, design and production of genetically modified cells and DNA vectors, and the control of peptide expression.

Licensor Channel Technology means Licensors current and future technology directed towards the design, identification, culturing, and/or production of genetically modified cells, including without limitation the technology embodied in the Licensor Materials and the Licensor IP, and specifically including without limitation the following of Licensors platform areas and capabilities (1) UltraVector®, (2) LEAP™, (3) DNA and RNA MOD engineering, (4) protein engineering, (5) transcription control chemistry, (6) genome engineering, and (7) cell system engineering.

Licensee Product means any product in the Field that is created, produced, developed, or identified in whole or in part, directly or indirectly, by or on behalf of Licensee during the Term through use or practice of Licensor Channel Technology, Licensor IP, or the Licensor Materials.

Field of Use

The Field means in humans the treatment of Ophthalmic-Local Diseases via administration of a Gene Therapeutic, and/or the treatment of Ophthalmic-Systemic Diseases via administration of a Gene Therapeutic without treating any broader systemic disease, including any systemic diseases associated with or causing such Ophthalmic-Systemic Disease.